Overview of Non–Muscle Invasive Bladder Cancer (NMIBC)

Treatment with nadofaragene led to a complete response rate of 75% at 3 months.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

“We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.

The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.